Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wilmott

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Journal for Immunotherapy of Cancer|June 10, 2022
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapyGrace Heloise Attrill, Carina N Owen, Tasnia Ahmed, et al.
The Journal of Pathology|October 20, 2011
The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitroBelamy B Cheung, Jessica Koach, Owen Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in MelanomaRicardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
Nature Communications|April 22, 2020
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionJenny H Lee, Elena Shklovskaya, Su Yin Lim, et al.
JCI Insight|September 29, 2022
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitisKazi J Nahar, Felix Marsh-Wakefield, Robert V Rawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain MetastasesJames S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
Pathology|October 31, 2015
Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomesJames S Wilmott, Matthew A Field, Peter A Johansson, et al.
NPJ Precision Oncology|January 22, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanomaYizhe Mao, Tuba N Gide, Nigel G Maher, et al.
Nature|February 12, 2019
Author Correction: Tissue-resident memory CD8<sup>+</sup> T cells promote melanoma-immune equilibrium in skinSimone L Park, Anthony Buzzai, Jai Rautela, et al.
Nature|January 2, 2019
Tissue-resident memory CD8<sup>+</sup> T cells promote melanoma-immune equilibrium in skinSimone L Park, Anthony Buzzai, Jai Rautela, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Journal for Immunotherapy of Cancer|June 10, 2022
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapyGrace Heloise Attrill, Carina N Owen, Tasnia Ahmed, et al.
The Journal of Pathology|October 20, 2011
The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitroBelamy B Cheung, Jessica Koach, Owen Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in MelanomaRicardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
Nature Communications|April 22, 2020
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionJenny H Lee, Elena Shklovskaya, Su Yin Lim, et al.
JCI Insight|September 29, 2022
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitisKazi J Nahar, Felix Marsh-Wakefield, Robert V Rawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain MetastasesJames S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
Pathology|October 31, 2015
Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomesJames S Wilmott, Matthew A Field, Peter A Johansson, et al.
NPJ Precision Oncology|January 22, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanomaYizhe Mao, Tuba N Gide, Nigel G Maher, et al.
Nature|February 12, 2019
Author Correction: Tissue-resident memory CD8<sup>+</sup> T cells promote melanoma-immune equilibrium in skinSimone L Park, Anthony Buzzai, Jai Rautela, et al.
Nature|January 2, 2019
Tissue-resident memory CD8<sup>+</sup> T cells promote melanoma-immune equilibrium in skinSimone L Park, Anthony Buzzai, Jai Rautela, et al.
Pageof 17